Key result
SGLT2i cut CV death or HF hospitalization by ~20% versus placebo in HFpEF.
This review outlines the diagnosis and management of HFpEF, highlighting SGLT2 inhibitors, exercise, weight loss, and diuretics as first-line therapies.
No takes yet. Share an insight, caveat, or question.
Affirms SGLT2 inhibitors for event reduction in HFpEF; supports consensus while leaving optimal adjunctive strategies open.
Redfield et al. (2023) studied this question. Sodium-glucose cotransporter type 2 inhibitors reduced heart failure hospitalization or cardiovascular death by approximately 20% compared with placebo in patients with HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: